Research Paper Volume 13, Issue 21 pp 24136—24154
Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort
Figure 1. The mutational pattern of 34 DDR genes among 1363 patients treated with ICB agents. The left panel represents gene mutation rates, the upper panel indicates the non-synonymous mutation counts of each patient, the middle panel shows mutational landscape of all DDR genes with distinct mutation types color coded distinctly, and the bottom panel displays clinical characteristics such as age, gender, drug target, TMB, and cancer subtype.